Efficacy of chemotherapy in epidermal growth factor receptor (EGFR) mutated metastatic pulmonary adenocarcinoma patients who had acquired resistance to first-line EGFR tyrosine kinase inhibitor (TKI)

Yen Han Tseng, Hsiu Ying Hung, Yi Chen Sung, Yen Chiang Tseng, Yu Chin Lee, Jacqueline Whang-Peng, Yuh Min Chen

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Introduction: Salvage chemotherapy is frequently used when tumour epidermal growth factor receptor (EGFR) mutated patients experience disease progression with first-line EGFR-tyrosine kinase inhibitor (TKI) treatment. However, the efficacy of salvage chemotherapy is still unknown. Methods: We retrospectively reviewed the chart records of our pulmonary adenocarcinoma patients between 2010 and 2013. Results: Five hundred and six of the 1240 stage IV adenocarcinoma patients had an EGFR mutation and 338 received first-line EGFR-TKI treatment. In all, 169 patients in this group received salvage chemotherapy after failure of EGFR-TKI, and 102 patients were eligible for this study. The chemotherapy response rate of these 102 patients was 24.5%, with a median progression-free survival (PFS) of 4.5?months, and median survival time was 14.6?months. Patients who received pemetrexed-based chemotherapy had longer PFS and overall survival (OS), although the extent was statistically insignificant. Progression-free survival and OS were longer for patients who received combination chemotherapy than single-agent chemotherapy. Conclusions: Pemetrexed-based combination chemotherapy is preferred before a more efficient treatment strategy is found.

Original languageEnglish
Pages (from-to)50-58
Number of pages9
JournalJournal of Chemotherapy
Volume28
Issue number1
DOIs
Publication statusPublished - Jan 2 2016
Externally publishedYes

Fingerprint

Epidermal Growth Factor Receptor
Protein-Tyrosine Kinases
Drug Therapy
Pemetrexed
Disease-Free Survival
Combination Drug Therapy
Survival
Adenocarcinoma of lung
Disease Progression
Adenocarcinoma
Therapeutics
Mutation
Neoplasms

Keywords

  • Adenocarcinoma
  • Epidermal growth factor receptor (EGFR)
  • Tyrosine kinase inhibitors (TKIs)

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Cite this

Efficacy of chemotherapy in epidermal growth factor receptor (EGFR) mutated metastatic pulmonary adenocarcinoma patients who had acquired resistance to first-line EGFR tyrosine kinase inhibitor (TKI). / Tseng, Yen Han; Hung, Hsiu Ying; Sung, Yi Chen; Tseng, Yen Chiang; Lee, Yu Chin; Whang-Peng, Jacqueline; Chen, Yuh Min.

In: Journal of Chemotherapy, Vol. 28, No. 1, 02.01.2016, p. 50-58.

Research output: Contribution to journalArticle

@article{96e8803fcf16480c8619a69014b0d0cc,
title = "Efficacy of chemotherapy in epidermal growth factor receptor (EGFR) mutated metastatic pulmonary adenocarcinoma patients who had acquired resistance to first-line EGFR tyrosine kinase inhibitor (TKI)",
abstract = "Introduction: Salvage chemotherapy is frequently used when tumour epidermal growth factor receptor (EGFR) mutated patients experience disease progression with first-line EGFR-tyrosine kinase inhibitor (TKI) treatment. However, the efficacy of salvage chemotherapy is still unknown. Methods: We retrospectively reviewed the chart records of our pulmonary adenocarcinoma patients between 2010 and 2013. Results: Five hundred and six of the 1240 stage IV adenocarcinoma patients had an EGFR mutation and 338 received first-line EGFR-TKI treatment. In all, 169 patients in this group received salvage chemotherapy after failure of EGFR-TKI, and 102 patients were eligible for this study. The chemotherapy response rate of these 102 patients was 24.5{\%}, with a median progression-free survival (PFS) of 4.5?months, and median survival time was 14.6?months. Patients who received pemetrexed-based chemotherapy had longer PFS and overall survival (OS), although the extent was statistically insignificant. Progression-free survival and OS were longer for patients who received combination chemotherapy than single-agent chemotherapy. Conclusions: Pemetrexed-based combination chemotherapy is preferred before a more efficient treatment strategy is found.",
keywords = "Adenocarcinoma, Epidermal growth factor receptor (EGFR), Tyrosine kinase inhibitors (TKIs)",
author = "Tseng, {Yen Han} and Hung, {Hsiu Ying} and Sung, {Yi Chen} and Tseng, {Yen Chiang} and Lee, {Yu Chin} and Jacqueline Whang-Peng and Chen, {Yuh Min}",
year = "2016",
month = "1",
day = "2",
doi = "10.1179/1973947815Y.0000000027",
language = "English",
volume = "28",
pages = "50--58",
journal = "Journal of Chemotherapy",
issn = "1120-009X",
publisher = "Maney Publishing",
number = "1",

}

TY - JOUR

T1 - Efficacy of chemotherapy in epidermal growth factor receptor (EGFR) mutated metastatic pulmonary adenocarcinoma patients who had acquired resistance to first-line EGFR tyrosine kinase inhibitor (TKI)

AU - Tseng, Yen Han

AU - Hung, Hsiu Ying

AU - Sung, Yi Chen

AU - Tseng, Yen Chiang

AU - Lee, Yu Chin

AU - Whang-Peng, Jacqueline

AU - Chen, Yuh Min

PY - 2016/1/2

Y1 - 2016/1/2

N2 - Introduction: Salvage chemotherapy is frequently used when tumour epidermal growth factor receptor (EGFR) mutated patients experience disease progression with first-line EGFR-tyrosine kinase inhibitor (TKI) treatment. However, the efficacy of salvage chemotherapy is still unknown. Methods: We retrospectively reviewed the chart records of our pulmonary adenocarcinoma patients between 2010 and 2013. Results: Five hundred and six of the 1240 stage IV adenocarcinoma patients had an EGFR mutation and 338 received first-line EGFR-TKI treatment. In all, 169 patients in this group received salvage chemotherapy after failure of EGFR-TKI, and 102 patients were eligible for this study. The chemotherapy response rate of these 102 patients was 24.5%, with a median progression-free survival (PFS) of 4.5?months, and median survival time was 14.6?months. Patients who received pemetrexed-based chemotherapy had longer PFS and overall survival (OS), although the extent was statistically insignificant. Progression-free survival and OS were longer for patients who received combination chemotherapy than single-agent chemotherapy. Conclusions: Pemetrexed-based combination chemotherapy is preferred before a more efficient treatment strategy is found.

AB - Introduction: Salvage chemotherapy is frequently used when tumour epidermal growth factor receptor (EGFR) mutated patients experience disease progression with first-line EGFR-tyrosine kinase inhibitor (TKI) treatment. However, the efficacy of salvage chemotherapy is still unknown. Methods: We retrospectively reviewed the chart records of our pulmonary adenocarcinoma patients between 2010 and 2013. Results: Five hundred and six of the 1240 stage IV adenocarcinoma patients had an EGFR mutation and 338 received first-line EGFR-TKI treatment. In all, 169 patients in this group received salvage chemotherapy after failure of EGFR-TKI, and 102 patients were eligible for this study. The chemotherapy response rate of these 102 patients was 24.5%, with a median progression-free survival (PFS) of 4.5?months, and median survival time was 14.6?months. Patients who received pemetrexed-based chemotherapy had longer PFS and overall survival (OS), although the extent was statistically insignificant. Progression-free survival and OS were longer for patients who received combination chemotherapy than single-agent chemotherapy. Conclusions: Pemetrexed-based combination chemotherapy is preferred before a more efficient treatment strategy is found.

KW - Adenocarcinoma

KW - Epidermal growth factor receptor (EGFR)

KW - Tyrosine kinase inhibitors (TKIs)

UR - http://www.scopus.com/inward/record.url?scp=84978698016&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84978698016&partnerID=8YFLogxK

U2 - 10.1179/1973947815Y.0000000027

DO - 10.1179/1973947815Y.0000000027

M3 - Article

C2 - 25976428

AN - SCOPUS:84978698016

VL - 28

SP - 50

EP - 58

JO - Journal of Chemotherapy

JF - Journal of Chemotherapy

SN - 1120-009X

IS - 1

ER -